文献速递临床试验与 GCP真实世界研究与卫生经济

机器人对比腹腔镜手术治疗中低位直肠癌:REAL随机临床试验

Robotic vs Laparoscopic Surgery for Middle and Low Rectal Cancer: The REAL Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01

这项多中心优效性随机临床试验纳入中国11个中心的中低位直肠腺癌患者,1:1随机接受机器人或传统腹腔镜直肠癌切除术。主要分析1171例,机器人组3年局部区域复发率1.6% vs 腹腔镜组4.0%(HR 0.45,95%CI 0.22-0.92),3年无病生存率机器人组87.2% vs 腹腔镜组83.4%(HR 0.74,95%CI 0.56-0.98),3年总生存率两组无显著差异。

要点

  • 机器人组3年局部区域复发率1.6%,低于腹腔镜组的4.0%(HR 0.45,log-rank P=.03)。
  • 机器人组3年无病生存率87.2%,高于腹腔镜组的83.4%(HR 0.74,log-rank P=.04)。
  • 两组3年总生存率无显著差异(机器人组94.7% vs 腹腔镜组93.0%)。

核心结论

  • 与腹腔镜手术相比,机器人手术显著改善中低位直肠癌患者的长期肿瘤学结局。
  • 结合更多真实世界临床数据与现代改进的外科医生培训项目,机器人手术可能成为中低位直肠癌患者的首选。

研究设计与样本

  • 多中心、优效性、随机临床试验,纳入中低位直肠腺癌(cT1-T3、N0-N1或ycT1-T3 Nx)且无远处转移的患者。
  • 2016年7月至2020年12月在中国8个省份的11个中心入组,评估1742例连续患者,1240例符合条件并随机分组。
  • 随访持续至2023年12月31日;患者1:1随机接受机器人或传统腹腔镜直肠癌切除术。
  • 主要分析按随机分组进行,但排除随机后判定不合格的患者;1171例纳入主要分析(机器人组586例,腹腔镜组585例)。

主要发现

  • 中位随访时间43.0个月(IQR,36.7-60.0个月)。
  • 3年局部区域复发率机器人组1.6%(95%CI,0.6%-2.6%)vs 腹腔镜组4.0%(95%CI,2.4%-5.6%)(HR 0.45,95%CI 0.22-0.92,log-rank P=.03;校正HR 0.39,95%CI 0.19-0.80)。
  • 3年无病生存率机器人组87.2% vs 腹腔镜组83.4%(HR 0.74,95%CI 0.56-0.98,log-rank P=.04;校正HR 0.67,95%CI 0.50-0.89)。
  • 3年总生存率机器人组94.7% vs 腹腔镜组93.0%,两组无显著差异。
  • 机器人组术后3个月和6个月的排尿功能、男女性和排便功能均更好,术后12个月排尿功能和男性性功能更好。

临床怎么用

  • 作者认为,与腹腔镜手术相比,机器人手术显著改善了中低位直肠癌患者的长期肿瘤学结局。
  • 作者认为,结合更多真实世界临床数据与现代改进的外科医生培训项目,机器人手术可能成为中低位直肠癌患者的首选。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Robotic surgery for rectal cancer is widely used, but data on long-term oncological outcomes are still lacking. OBJECTIVE: To compare the 3-year locoregional recurrence rates of middle and low rectal cancer in patients who underwent robotic surgery vs conventional laparoscopic surgery. DESIGN, SETTING, AND PARTICIPANTS: In this multicenter, superiority, randomized clinical trial, patients with middle or low rectal adenocarcinoma (cT1-T3, N0-N1, or ycT1-T3 Nx) and no distant metastasis were enrolled at 11 centers across 8 provinces in China from July 2016 to December 2020. Among the 1742 consecutive patients assessed for eligibility, 1240 were eligible and randomized. Follow-up continued until December 31, 2023. INTERVENTIONS: Patients were randomized 1:1 to undergo robotic or conventional laparoscopic rectal cancer resection. MAIN OUTCOMES AND MEASURES: The primary outcome was the 3-year locoregional recurrence rate. The primary analysis was performed as randomized, but excluded patients deemed ineligible after randomization. The secondary outcomes included disease-free survival; overall survival; and urinary, sexual, and defecation function. RESULTS: Of the 1240 patients enrolled, 1171 were included in the primary analysis (586 in the robotic surgery group; mean age, 59.1 [SD, 11.0] years; and 356 were men [60.8%] vs 585 in the laparoscopic surgery group; mean age, 60.7 [SD, 9.8] years; and 354 were men [60.5%]). The median follow-up time was 43.0 months (IQR, 36.7-60.0 months). The 3-year locoregional recurrence rate was 1.6% (95% CI, 0.6%-2.6%) in the robotic group vs 4.0% (95% CI, 2.4%-5.6%) in the laparoscopic group (hazard ratio [HR], 0.45 [95% CI, 0.22-0.92], log-rank P = .03; adjusted HR, 0.39 [95% CI, 0.19-0.80]). The 3-year disease-free survival rate was higher in the robotic group (87.2%) vs the laparoscopic group (83.4%) (HR, 0.74 [95% CI, 0.56-0.98], log-rank P = .04; adjusted HR, 0.67 [95% CI, 0.50-0.89]). No significant between-group difference was observed in 3-year overall survival (94.7% in the robotic group vs 93.0% in the laparoscopic group). Patients in the robotic group also had better urinary function, male and female sexual function, and defecation function at 3 and 6 months after surgery and better urinary function and male sexual function at 12 months after surgery. CONCLUSIONS AND RELEVANCE: Compared with conventional laparoscopic surgery, robotic surgery significantly improved long-term oncological outcomes in patients with middle or low rectal cancer. With additional real-world clinical data and modern, improved training programs for surgeons, robotic surgery could be the preferred choice for patients with middle or low rectal cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02817126.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Feng Q, Yuan W, Li T, et al. Robotic vs Laparoscopic Surgery for Middle and Low Rectal Cancer: The REAL Randomized Clinical Trial. JAMA. 2025. PMID: 40455621. doi:10.1001/jama.2025.8123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。